Bal Pharma share news, announcements and annual reports

NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap

Bal Pharma Limited · Face value ₹10 · Listed Apr 1995 on BSE, May 2006 on NSE

₹81.85₹2.76 (3.26%)BSE ₹81.20

Share price at the NSE close on 30 Oct 2026. Previous close ₹84.61.

30 Oct: open ₹84.05, high ₹84.05, low ₹81.21

52-week range of traded prices to 30 Oct 2026

₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026

Delivery only: shares bought must be paid for in full, with no selling on the same day.

Market cap: ₹130 Cr2,779th largest listed
P/E: 18.08
P/B: 1.58
Dividend yield: 1.47%
ROE: 9.0%
ROCE: 9.3%
Debt to equity: 1.94
Volume, NSE: 6,401

Bal Pharma share news and announcements

549 announcements, routine notices left out, newest first. Page 8 of 11.

Mar 2018
- 26 Mar · Updates
  Disclosure as per Regulation 30 of the SEBI ( LODR) Regulations.
- 23 Mar · Updates
  Disclosure as per Regulation 30 of the SEBI (LODR) Regulations.
- 6 Mar · Business
  Press release dated March 06, 2018, titled " AKAAL PHARMA PTY LTD AND BAL PHARMA LTD TO DEVELOP NOVEL VETERINARY THERAPEUTICS ".March 6, 2018 Akaal Pharma Pty Ltd, Melbourne, Australia (herein Akaal Pharma) and Bal Pharma Ltd, Bangalore, India (herein Bal Pharma) today announce a collaboration and the launch of Joint Venture Company AB VET Pharma Pty Ltd (herein AB VET). The new joint venture will be completely funded by Bal Pharma to develop Akaal Pharma's IP within the veterinary field. The first veterinary indication will be against atopic dermatitis (AD) in dogs. Akaal's ABV-119 is the first of its kind oral drug candidate for the treatment of AD in dogs. ABV-119 is a multimodal therapy that includes anti-inflammatory/ immune modulatory and anti-itch effects. AB VET plans to begin clinical development in H1 2018. Atopic Dermatitis is a chronic disease affecting pets from early age. ABV-119 addresses significant gaps in the current treatment regimen and has global patent protection. Bal Pharma's extensive global reach and manufacturing capabilities would support the research efforts of Akaal and will strengthen the Joint Venture. We are very excited to co-develop the intellectual property for vet applications and make it available to pet owners globally, said Mr. Shailesh Siroya, Managing Director of Bal Pharma. We are pleased to have Bal Pharma as a strategic partner to develop a first-in-class in oral drug treatment against AD in dogs. This partnership further strengthens Akaal Pharma's drug discovery platform and opens the door to new opportunities in the veterinary field, said Mr Bagicha S Sandhu, Chairman of Akaal Pharma.About Dog Atopic Dermatitis Atopic dermatitis has underlying multiple pathological features with inflammation, immune hyperactivity and vascular barrier disruption. Dogs with atopic dermatitis are usually itchy. The inflamed lesions and recurrent infections are quite common in these patients. The symptoms usually start at early age when the dog is 1 to 5 years old. There is undermet need of atopic dermatitis for a safe and effective oral drug.About Akaal Pharma Akaal Pharma is an Australian clinical-stage drug discovery and development company focused on developing novel drugs for the treatment of inflammation and immune diseases. Akaal through its prorietary drug discovery platform has created a pipeline of anti-inflammatory drugs with multiple applications. Akaal Pharma has strong portfolio of intellectual property/patents on its internally discovered drug candidates. For more information, visit www.akaalpharma.comAbout Bal Pharma Bal Pharma, an Indian Pharmaceutical Company with 25 years of experience, specialized in Prescription Drugs, and Bulk Actives, supplying bulk drugs and formulations across 60 countries through its network. Bal Pharma also brings novel drugs to the market, including Ayurvedic and Herbal medicines. Contacts:Bal Pharma Pvt Ltd: 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560052. Tel +91709-026-9000, Email: mdsect@balpharma.comAkaal Pharma Pty Ltd:Thomas Cherry Building, #301E, La Trobe University, Bundoora, VIC-3083, Australia. Tel: +61-3-9479-2584. Email: info@akaalpharma.com Certain statements in this new release concerning Akaal Pharma and Bal Pharma business are considered forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all the forward-looking statements in this press release can be affected by inaccurate assumptions Akaal Pharma or Bal Pharma might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of drug development; uncertainties as to the future success. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Akaal Pharma or Bal Pharma undertakes no obligation to publicly update forward-looking statem
Feb 2018
- 14 Feb · Board meeting
  Outcome of Board Meeting held on February 14, 2018.
- 14 Feb · Results
  Financial results for the period ended December 31, 2017.
- 12 Feb · Updates
  Has submitted to the exchange a copy of newspaper Advertisement-Reg Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules,2016.
Jan 2018
- 29 Jan · Board meeting
  Board of Directors inter alia will be considering approval of un audited stand alone and consolidated financial results of the Company for the quarter ended December 31, 2017.
Dec 2017
- 11 Dec · Results
  Financial results for the period ended September 30, 2017.
Nov 2017
- 15 Nov · Board meeting
  Inter alia will be considering approval of un audited stand alone and consolidated financial results of the Company for the quarter and half year ended September 30, 2017.
Oct 2017
- 31 Oct · Management
  Resignation of Mr Shrenik D Siroya as Non- Executive Director of the company w.e.f. October 31, 2017.
Sep 2017
- 22 Sep · Meeting
  Copy Srutinizers report of Annual General Meeting held on September 22, 2017. Further, the company has informed the Exchange regarding voting results.
- 22 Sep · Meeting
  Proceedings of Annual General Meeting held on September 22, 2017
- 14 Sep · Updates
  Submission of news paper publications.In compliance with Regulation 47 of SEBI(LODR) Regulation.
- 13 Sep · Corrigendum
  Corrigendum to Notice of Annual General Meeting to be held on September 22, 2017
- 13 Sep · Legal
  Exchange had sought clarification from Bal Pharma Limited with respect to announcement dated 12-Sep-2017, regarding " Outcome of Board Meeting held on September 11, 2017." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached.
- 12 Sep · Legal
  Exchange has sought clarification from Bal Pharma Limited with respect to announcement dated 12-Sep-2017, regarding " Outcome of Board Meeting held on September 11, 2017." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.
- 12 Sep · Board meeting
  Outcome of Board Meeting held on September 11, 2017.
- 11 Sep · Results
  Financial results for the period ended June 30, 2017.
- 1 Sep · Meeting
  Notice of Annual General Meeting to be held on September 22, 2017
Aug 2017
- 29 Aug · Board meeting
  Inter alia will be considering approval of Ind-AS compliant, un-audited stand alone and consolidated financial results of the Company for the quarter ended June 30, 2017.
- 29 Aug · Updates
  Sub : Submission of News Paper Publications. Ref : Regulation 47 of SEBI (LODR) Regulations, 2015. With reference to the above, we are submitting to the exchange copies of the newspaper advertisements pertaining to Notice for 30th Annual General Meeting of the Company scheduled on 22nd September 2017, Book closure and remote e-voting intimations published in Financial Express (English language) and Sanje Vani (Kannada Language) newspapers, on 28th August 2017. Please take this submissions on record.bmission of News Paper Advertisements regarding AGM notice & Book Closure.
- 10 Aug · Meeting
  Company close the Register of Members and Share Transfer Books of the Company from September 18 ,2017 to September 22, 2017 (both days inclusive) for ascertaining the entitlement of dividend recommended by the Board at their meeting held on May 30, 2017 and for the Annual General Meeting of the Company scheduled to be held on September 22, 2017.
Jul 2017
- 28 Jul · Board meeting
  Inter alia will be transacting the following business. 1.To approve the 30th Annual General Meeting Notice (AGM), Directors Report and Corporate Governance reports of the Company, for the financial year ended March 31, 2017. 2. To decided on the Book closure dates. 3. To consider other AGM related matters
May 2017
- 30 May · Results
  Financial results for the period ended March 31, 2017.
- 30 May · Board meeting
  Outcome of Board Meeting held on May 30, 2017.
- 30 May · Dividend
  Board of Directors at its meeting held on May 30, 2017, recommended Final Dividend of Re. 1 per equity share.
- 12 May · Board meeting
  Inter alia, Considering approval of audited stand alone and consolidated financial results of the Company for the financial year 2016.17. Further, pursuant to Prohibition of Insider Trading Regulations,2015 of SEBI and as per the provisions of Code of Conduct of the Company, the trading window on the designated employees of the Company and their immediate relatives will remain closed from 12.05.2017 up to 31.05.2017.
- 3 May · Restructuring
  Company has decided to issue notice as per the provisions of Section 25 FFA read with Section 25 F of the Industrial Disputes Act, 1947, pertaining to its parenterals and IV fluids manufacturing facility at Pune. This decision was taken as part of the restructuring exercise undertaken by the Company to streamline its operations and to exit from its noncore businesses, whose operational costs are significant but generate very nominal revenues.
Apr 2017
- 5 Apr · Disclosure
  Subba rao Prasanna,Anita Siroya,Anand Surana, Monica Surana, Dilip Surana, Dilip Surana ( HUF), Micro Labs Limited,Archana Surana,Jivi Dheerajmal Siroya,Chdraprakash Dheerajmal Siroya and Shrenik Siroya has submitted to the Exchange vide letter dated April 03 , 2017 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
- 3 Apr · Disclosure
  Vide letter dated March 31, 2017 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Feb 2017
- 7 Feb · Results
  Financial results for the period ended December 31, 2016.
Jan 2017
- 25 Jan · Board meeting
  To inter alia take on record and approve the Un-Audited financial results of the Company for the quarter ended December 31, 2016. Further, pursuant to Prohibition of Insider Trading Regulations,2015 of SEBI and as per the provisions of Code of Conduct of the Company, the trading window on the designated employees of the Company and their immediate relatives shall remain closed from January 25, 2017 up to February 08, 2017. .
Nov 2016
- 14 Nov · Results
  Financial results for the period ended September 30, 2016.
Oct 2016
- 28 Oct · Board meeting
  Inter alia take on record and approve the Un-Audited financial results of the Company for the quarter and half year ended September 30, 2016.
Sep 2016
- 24 Sep · Regulation 44(3) of SEBI (LODR), Reg., 2015
  Details of voting results of the Annual General Meeting of the Company held on the September 22, 2016 along with Scrutinizers Report.
- 22 Sep · Meeting
  Proceedings of Annual General Meeting of the Company held on September 22, 2016.
Aug 2016
- 29 Aug · Management
  Board of Directors of the Company at their meeting held on August 29, 2016 has appointed Mr. Akash Mathur as the Chief Executive Officer of the Company, with effect from September 1, 2016. Mr. Mathur has vast pharma experience in US & Canada including a startup and advisory role to several small and medium Companies, followed by 10 years of leading life sciences business for Companies of DRL and TATA Group, thereby bringing an international orientation and systems implementation to their businesses, before jointing Bal Pharma Ltd.
- 26 Aug · Meeting
  Notice of Annual General Meeting of the members of the Company to be held on September 22, 2016 along with Annual Report.
- 10 Aug · Meeting
  Register of Members & Share Transfer Books of the Company will remain closed from September 18, 2016 to September 22, 2016 (both days inclusive) for the purpose of Dividend and Annual General Meeting (AGM) of the Company to be held on September 22, 2016.
- 10 Aug · Results
  Standalone & consolidated financial results along with the Limited Review Report for the period ended June 30, 2016.
Jul 2016
- 19 Jul · Board meeting
  Sub : The Board of Directors inter alia will be transacting the following business. (1.) To take on record and approve the Un-audited financial results of the Company for the quarter ended June 30, 2016. (2).To approve the AGM Notice , Directors Report and Corporate Governance reports of the Company for the financial year ended March 31, 2016. (3). To decided on the Book closure dates for Financial Year 2015-16. 4. To consider other AGM related matters. 5. To consider certain key business propositions.
May 2016
- 26 May · Corrigendum
  With reference to the above and further to the submission to the exchange on the outcome of the board meeting held on May 25, 2016, we request you to kindly read the date of the letter as May 25, 2016 and the financial year for which the dividend is recommended by the board as March 31, 2016 instead of March 31, 2015, which was erroneously mentioned
- 26 May · Dividend
  Board of Directors of the Company at its meeting held on May 25, 2016, has recommended a dividend of Re.1/- per equity share of Rs.10/- each i.e. 10% on the paid up equity share capital of the Company, for the financial year ended March 31, 2016.
- 25 May · Results
  Standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.
- 10 May · Board meeting
  Inter alia will be transacting the following business,1. To take on record and approve the audited financial results of the Company for the financial year ended March 31, 2016.2. Appropriation of profits including recommendation of dividend if any, for the F.Y 2015.16.3. To consider various other A.G.M related aspects.
Apr 2016
- 13 Apr · Business
  Board of Directors of the Company at their meeting held on April 13, 2016 has inter alia approved the allotment of 13,00,000 equity shares of Rs.10/- each with a premium of Rs.52/- per share of the Company on preferential basis to the investors who has exercised the conversion option on 13,00,000 warrants subscribed by them.
- 6 Apr · Board meeting
  Inter alia, to consider allotment of equity shares to the investors upon conversion of warrants.
- 1 Apr · Disclosure
  Vide letter dated April 1, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
Feb 2016
- 24 Feb · Rating
  ICRA has revised its long term credit rating of Bal Pharma Ltd to BBB (Pronounced as triple B) from BBB- (pronounced triple B minus) assigned by ICRA for the previous financial year.ICRA also have revised the short term credit rating of Bal Pharma Ltd to A3+ (Pronounced A three plus) from A 3 ( pronounced as A three) assigned for last financial year 2014.15.The up gradation of crediting rating of the Company is the indication of its significant improvement in the financial profile by expanding its margins and improvised cash flows.
- 10 Feb · Results
  Standalone & consolidated financial results along with the Limited Review Report for the period ended December 31, 2015.

Bal Pharma share news and announcements

Mar 2018

Feb 2018

Jan 2018

Dec 2017

Nov 2017

Oct 2017

Sep 2017

Aug 2017

Jul 2017

May 2017

Apr 2017

Feb 2017

Jan 2017

Nov 2016

Oct 2016

Sep 2016

Aug 2016

Jul 2016

May 2016

Apr 2016

Feb 2016